UBS Group AG Boosts Stock Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

UBS Group AG lifted its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Rating) by 7.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 524,473 shares of the company’s stock after buying an additional 34,710 shares during the quarter. UBS Group AG owned about 0.13% of GoodRx worth $2,449,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of GoodRx during the third quarter worth $93,000. Aigen Investment Management LP purchased a new position in GoodRx during the third quarter valued at approximately $74,000. Levin Capital Strategies L.P. purchased a new stake in GoodRx in the 3rd quarter worth approximately $47,000. Virtu Financial LLC bought a new position in GoodRx in the 3rd quarter valued at $72,000. Finally, Inspire Advisors LLC purchased a new position in shares of GoodRx during the 3rd quarter valued at $156,000. 35.22% of the stock is owned by institutional investors.

GoodRx Stock Down 6.8 %

NASDAQ GDRX opened at $5.52 on Tuesday. GoodRx Holdings, Inc. has a 1 year low of $3.82 and a 1 year high of $20.59. The stock has a market capitalization of $2.19 billion, a PE ratio of -78.85, a PEG ratio of 12.41 and a beta of 0.84. The company has a debt-to-equity ratio of 0.80, a current ratio of 12.05 and a quick ratio of 12.05. The business’s 50-day moving average is $5.24 and its 200 day moving average is $5.25.

Wall Street Analysts Forecast Growth

GDRX has been the topic of a number of recent analyst reports. Truist Financial lowered their price objective on GoodRx to $6.00 in a research report on Wednesday, November 16th. Barclays cut their price objective on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Wednesday, January 18th. Credit Suisse Group lowered their target price on shares of GoodRx from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Thursday, March 2nd. Morgan Stanley cut their price target on shares of GoodRx from $10.00 to $6.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 9th. Finally, The Goldman Sachs Group lowered their price objective on shares of GoodRx from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 1st. Thirteen analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $7.92.

GoodRx Profile

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.